RO93650B - Procedeu pentru obtinerea unei polipeptide umane fiziologic activa - Google Patents

Procedeu pentru obtinerea unei polipeptide umane fiziologic activa

Info

Publication number
RO93650B
RO93650B RO118239A RO11823985A RO93650B RO 93650 B RO93650 B RO 93650B RO 118239 A RO118239 A RO 118239A RO 11823985 A RO11823985 A RO 11823985A RO 93650 B RO93650 B RO 93650B
Authority
RO
Romania
Prior art keywords
human
necrosis factor
polypeptide
active human
physiologically active
Prior art date
Application number
RO118239A
Other languages
English (en)
Other versions
RO93650A (ro
Inventor
Bruce Wallce Robert
Itoh Hirataka
Original Assignee
Asahi Kasei Kogyo Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Kogyo Kabushiki Kaisha filed Critical Asahi Kasei Kogyo Kabushiki Kaisha
Publication of RO93650A publication Critical patent/RO93650A/ro
Publication of RO93650B publication Critical patent/RO93650B/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/948—Microorganisms using viruses or cell lines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Image Analysis (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

Inventia se refera la un procedeu pentru obtinerea unei polipeptide umane, fiziologic activa, de tipul factor uman de necroza a tumorilor (TNF uman), care cuprinde obtinerea de DNA, care codifica o polipeptida umana fiziologic activa, cu activitate de factor uman de necroza a tumorilor, includerea DNA-ului într-un vector adecvat, replicabil si transformarea cu ajutorul acestui vector a celulelor unui microorganism sau ale unei culturi de celule, cultivarea celulelor transformate cu ajutorul vectorului replicabil si obtinerea factorului uman de necroza a tumorilor. Procedeul, conform inventiei, permite obtinerea, într-un mod avantajos, a unei cantitati suficiente de polipeptida umana pura, fiziologic activa, de tipul factor uman de necroza a tumorilor. Acest factor induce necroza tumorilor fara a avea efecte toxice asupra tesuturilor normale ale corpului.
RO118239A 1984-04-06 1985-04-02 Procedeu pentru obtinerea unei polipeptide umane fiziologic activa RO93650B (ro)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/597,372 US4879226A (en) 1984-04-06 1984-04-06 Novel human physiologically active polypeptide

Publications (2)

Publication Number Publication Date
RO93650A RO93650A (ro) 1988-03-30
RO93650B true RO93650B (ro) 1988-03-31

Family

ID=24391235

Family Applications (1)

Application Number Title Priority Date Filing Date
RO118239A RO93650B (ro) 1984-04-06 1985-04-02 Procedeu pentru obtinerea unei polipeptide umane fiziologic activa

Country Status (39)

Country Link
US (1) US4879226A (ro)
EP (2) EP0354592A1 (ro)
JP (1) JPS60252496A (ro)
KR (1) KR920007399B1 (ro)
AR (1) AR240475A1 (ro)
AU (2) AU595480B2 (ro)
BE (1) BE902119A (ro)
BG (1) BG43355A3 (ro)
BR (1) BR8501624A (ro)
CA (1) CA1341348C (ro)
CH (2) CH672790A5 (ro)
DD (1) DD251785A5 (ro)
DK (1) DK151985A (ro)
EG (1) EG17965A (ro)
ES (1) ES8704976A1 (ro)
FI (1) FI86992C (ro)
FR (1) FR2564097B1 (ro)
GB (1) GB2158829B (ro)
GR (1) GR850836B (ro)
HK (1) HK102192A (ro)
HU (1) HUT37813A (ro)
IE (1) IE58833B1 (ro)
IL (1) IL74804A (ro)
IN (1) IN163653B (ro)
IT (1) IT1218469B (ro)
JO (1) JO1365B1 (ro)
LU (1) LU85835A1 (ro)
MA (1) MA20402A1 (ro)
MT (1) MTP963B (ro)
MY (1) MY101887A (ro)
NO (1) NO174473C (ro)
NZ (2) NZ211666A (ro)
OA (1) OA07983A (ro)
PL (1) PL156392B1 (ro)
PT (1) PT80239B (ro)
RO (1) RO93650B (ro)
SG (1) SG77892G (ro)
YU (1) YU57885A (ro)
ZA (1) ZA852563B (ro)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0695939B2 (ja) * 1983-12-02 1994-11-30 大日本製薬株式会社 ウサギ癌壊死因子をコ−ドするクロ−ン化ｄνａ
JP2584206B2 (ja) * 1984-08-17 1997-02-26 大日本製薬株式会社 ヒト癌壊死因子
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
DE19975063I2 (de) * 1984-03-06 2005-08-18 Dainippon Pharmaceutical Co DNS den menschlichen Tumornekrosisfaktor kodierendund das menschliche Tumornekronisfaktor-Polypepti d.
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
JPS60228297A (ja) * 1984-04-24 1985-11-13 株式会社　東京タツノ 給油装置
US6686455B1 (en) * 1984-07-05 2004-02-03 Genentech, Inc. Tumor necrosis factor
GR851626B (ro) * 1984-07-05 1985-11-26 Genentech Inc
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
JP2675294B2 (ja) * 1984-10-15 1997-11-12 カイロン コーポレイション ヒト腫瘍壊死因子
WO1986002381A1 (en) * 1984-10-15 1986-04-24 Cetus Corporation Human tumor necrosis factor
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
JPS61124392A (ja) * 1984-11-22 1986-06-12 Asahi Chem Ind Co Ltd 遺伝子組換体の産生する生理活性物質の精製法
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
DE3585690D1 (de) * 1984-12-21 1992-04-23 Biogen Inc Reinigung, herstellung und verwendung von tumor-nekrosisfaktoren.
JPS6248634A (ja) * 1985-07-23 1987-03-03 Mochida Pharmaceut Co Ltd 新規アミノ酸組成物、その製造方法及び該アミノ酸組成物を含有する医療組成物
JPH0698004B2 (ja) * 1985-09-30 1994-12-07 サントリー株式会社 Ｔｎｆ発現用新規プラスミド
US5059530A (en) * 1985-09-30 1991-10-22 Suntory Ltd. Expression vector for human TNF
US4677197A (en) * 1985-10-30 1987-06-30 Cetus Corporation Purification method for tumor necrosis factor
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
US4828830A (en) * 1986-01-24 1989-05-09 Genentech, Inc. Method and composition for prophylaxis and treatment of viral infections
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
GB2194146A (en) * 1986-07-31 1988-03-02 Genentech Inc Treatment of retroviral infections
DE3716513A1 (de) * 1987-05-16 1988-11-24 Basf Ag Proteine mit tnf-wirkung
GB2217325B (en) * 1988-04-08 1991-11-20 British Bio Technology Synthetic gene for tumour necrosis factor alpha.
US5071834A (en) * 1988-09-16 1991-12-10 Genentech, Inc. Purified activin B composition
CA2003981C (en) * 1988-12-27 2000-06-13 Hiroshi Ishimaru Pharmaceutical compositions and use thereof in the treatment of psoriasis
US5342613A (en) * 1988-12-27 1994-08-30 Health Research Inc. Pharmaceutical compositions and use thereof in the treatment of psoriasis
AU648020B2 (en) * 1989-02-21 1994-04-14 Washington University Modified forms of reproductive hormones
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
DE69029970T2 (de) 1989-08-16 1997-06-19 Chiron Corp Zusammensetzungen zur hemmung der bildung von proteinhormon und deren verwendungen
EP0497922B1 (en) * 1989-10-24 2002-01-30 Chiron Corporation Infective protein delivery system
US5653974A (en) * 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
KR970005042B1 (ko) * 1993-02-09 1997-04-11 한일합성섬유공업 주식회사 종양괴사인자-알파 뮤테인
RU2139092C1 (ru) 1993-06-03 1999-10-10 Терапьютик Антибодиз Инк. Фрагменты антител в терапии
US6551623B1 (en) 1993-09-09 2003-04-22 Lorus Therapeutics Inc. Immunomodulating compositions from bile
EP0749494A1 (en) 1994-03-07 1996-12-27 Chiron Corporation Compositions for the inhibition of tnf formation and uses thereof
AU711294B2 (en) 1995-03-16 1999-10-07 Erin Mills Biotech Inc. Immunomodulating compositions from bile for the treatment of immune system disorders
US6001812A (en) * 1995-04-28 1999-12-14 Societe L'oreal S.A. Modulating body/cranial hair growth with derivatives of the α-type melanocyte-stimulating hormone
FR2733421B1 (fr) * 1995-04-28 1997-06-06 Oreal Utilisation de derives de l'hormone stimulatrice des melanocytes de type alpha pour stimuler ou induire la pousse des cheveux et/ou stopper leur chute
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
US7687461B2 (en) * 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US7244823B2 (en) * 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US7662367B2 (en) * 2000-03-02 2010-02-16 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-α related disorders
US20070172449A1 (en) * 2000-03-02 2007-07-26 Xencor, Inc. TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS
US7446174B2 (en) 2001-03-02 2008-11-04 Xencor, Inc. Protein based TNF-α variants for the treatment of TNF-α related disorders
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
US7056695B2 (en) 2000-03-02 2006-06-06 Xencor TNF-α variants
US6579522B1 (en) * 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
EP1399140A1 (en) * 2001-06-20 2004-03-24 Lorus Therapeutics Inc. Biological response modifier composition and uses thereof
US20030086903A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
US7628988B2 (en) * 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
US7582313B2 (en) 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
WO2004045376A2 (en) * 2002-11-15 2004-06-03 The General Hospital Corporation Screening methods to identify treatments for autoimmune disease
AU2003298816C1 (en) 2002-12-02 2010-12-16 Amgen Fremont, Inc. Antibodies directed to Tumor Necrosis Factor and uses thereof
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
JP2007511507A (ja) * 2003-11-14 2007-05-10 ジェンベク、インコーポレイティッド 癌を処置するための治療レジメン
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
WO2013025248A1 (en) 2011-08-12 2013-02-21 Mello Biotechnology, Inc. Inducable expression from the eukaryotic pol -2 promoter in prokaryotes
US10196662B2 (en) 2012-08-10 2019-02-05 Mello Biotechnology, Inc. Composition for producing microRNA precursors as drugs for enhancing wound healing and production method of the microRNA precursors
WO2014124134A1 (en) 2013-02-07 2014-08-14 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
ES2962885T3 (es) 2015-05-15 2024-03-21 Massachusetts Gen Hospital Anticuerpos antagonistas de la superfamilia del receptor del factor de necrosis tumoral
US11266730B2 (en) 2015-09-29 2022-03-08 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for BCG therapy
US11859002B2 (en) 2016-05-13 2024-01-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor 2 antibodies
US11103592B2 (en) 2016-11-09 2021-08-31 Philogen S.P.A. IL2 and TNF mutant immunoconjugates

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309418A (en) * 1980-03-25 1982-01-05 Sloan-Kettering Research Institute For Cancer Anti-tumor agent from human serum and process
US4359415A (en) * 1981-06-03 1982-11-16 University Of Tennessee Research Corporation Isolation of an antineoplastic protein fraction and an antineoplastic peptide fraction from human urine
SE8204382L (sv) * 1981-07-21 1983-01-22 Hayashibara Biochem Lab Sett att framstella malcellysfaktor och anvendning derav
JPS6011890B2 (ja) * 1981-12-21 1985-03-28 株式会社林原生物化学研究所 ツモアネクロシスフアクタ−の製造方法
JPS5821621A (ja) * 1981-07-31 1983-02-08 Hayashibara Biochem Lab Inc ヒトツモア・ネクロシス・ファクタ−を含有する悪性腫瘍治療剤
JPS57140725A (en) * 1981-12-28 1982-08-31 Dainippon Pharmaceut Co Ltd Physiologically active substance having carcinostatic action
JPS58141785A (ja) * 1982-02-16 1983-08-23 Nippon Shinyaku Co Ltd 抗腫瘍物質の製法
US4481137A (en) * 1982-02-26 1984-11-06 Mochida Pharmaceutical Co., Ltd. Glycoproteins and processes for their production
US4447355A (en) * 1982-04-07 1984-05-08 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing a tumor necrosis factor and a stable aqueous solution or powder containing the same
JPS591288A (ja) * 1982-06-29 1984-01-06 Sato :Kk 連続値札印字装置
AU8956582A (en) * 1982-10-06 1984-04-24 Makitsubo, T. Process for extracting tumor necrosis factor from macrophage
JPS59169492A (ja) * 1983-03-15 1984-09-25 Asahi Chem Ind Co Ltd ヒト融合細胞からの生理活性物質の産生方法
CA1265444A (en) * 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
JPS6019719A (ja) * 1983-07-15 1985-01-31 Asahi Chem Ind Co Ltd 抗腫瘍活性を有する蛋白質
JPS5943617Y2 (ja) * 1983-08-26 1984-12-25 株式会社潤工社 広い周波数帯域において均一な特性を有する伝送線路用導体
JPS60112718A (ja) * 1983-11-21 1985-06-19 Kyorin Pharmaceut Co Ltd 抗腫瘍作用を示す蛋白性物質及びその製造方法
JPH0695939B2 (ja) * 1983-12-02 1994-11-30 大日本製薬株式会社 ウサギ癌壊死因子をコ−ドするクロ−ン化ｄνａ
JPS60185799A (ja) * 1984-03-06 1985-09-21 Dainippon Pharmaceut Co Ltd ヒト癌壊死因子
DE19975063I2 (de) * 1984-03-06 2005-08-18 Dainippon Pharmaceutical Co DNS den menschlichen Tumornekrosisfaktor kodierendund das menschliche Tumornekronisfaktor-Polypepti d.
JPS60260522A (ja) * 1984-06-07 1985-12-23 Asahi Chem Ind Co Ltd 遺伝子組換体が生産する生理活性物質の安定化法
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
JPS61124392A (ja) * 1984-11-22 1986-06-12 Asahi Chem Ind Co Ltd 遺伝子組換体の産生する生理活性物質の精製法

Also Published As

Publication number Publication date
IT8520242A0 (it) 1985-04-05
PT80239A (en) 1985-05-01
IN163653B (ro) 1988-10-22
HUT37813A (en) 1986-02-28
DK151985A (da) 1985-10-07
FI86992C (fi) 1992-11-10
EG17965A (en) 1994-01-30
AU4016289A (en) 1989-12-07
EP0354592A1 (en) 1990-02-14
NZ211666A (en) 1990-01-29
HK102192A (en) 1992-12-24
JO1365B1 (en) 1986-11-30
CH672790A5 (ro) 1989-12-29
NO174473B (no) 1994-01-31
GR850836B (ro) 1985-06-26
PT80239B (pt) 1988-02-17
FR2564097A1 (fr) 1985-11-15
IT1218469B (it) 1990-04-19
NZ231317A (en) 1991-01-29
OA07983A (en) 1987-01-31
NO851400L (no) 1985-10-07
PL252807A1 (en) 1986-02-25
CA1341348C (en) 2002-03-19
AU595480B2 (en) 1990-04-05
CH675423A5 (ro) 1990-09-28
JPS60252496A (ja) 1985-12-13
LU85835A1 (fr) 1985-12-16
IL74804A0 (en) 1985-07-31
KR850007273A (ko) 1985-12-02
NO174473C (no) 1994-05-11
MY101887A (en) 1992-02-15
IE850863L (en) 1985-10-06
RO93650A (ro) 1988-03-30
GB2158829B (en) 1992-04-22
FI851336L (fi) 1985-10-07
YU57885A (en) 1989-02-28
EP0158286A2 (en) 1985-10-16
FI851336A0 (fi) 1985-04-03
BG43355A3 (en) 1988-05-16
IE58833B1 (en) 1993-11-17
MTP963B (en) 1985-11-25
FI86992B (fi) 1992-07-31
DD251785A5 (de) 1987-11-25
ES541920A0 (es) 1987-05-01
BE902119A (fr) 1985-10-04
BR8501624A (pt) 1985-12-03
ZA852563B (en) 1986-05-28
FR2564097B1 (fr) 1989-09-22
IL74804A (en) 1991-06-30
AU637054B2 (en) 1993-05-20
AU4088285A (en) 1985-10-10
ES8704976A1 (es) 1987-05-01
DK151985D0 (da) 1985-04-03
GB2158829A (en) 1985-11-20
MA20402A1 (fr) 1985-12-31
GB8508864D0 (en) 1985-05-09
SG77892G (en) 1992-10-02
JPH025760B2 (ro) 1990-02-05
PL156392B1 (pl) 1992-03-31
EP0158286A3 (en) 1987-05-13
US4879226A (en) 1989-11-07
AR240475A1 (es) 1990-04-30
KR920007399B1 (ko) 1992-08-31

Similar Documents

Publication Publication Date Title
RO93650B (ro) Procedeu pentru obtinerea unei polipeptide umane fiziologic activa
Miettinen et al. Keratin in the epithelial-like cells of classical biphasic synovial sarcoma
IT8547834A0 (it) Procedimento di trattamento di cellule con proteine ossee solubili per renderle idonee a stimolare la crescita di tessuti cartilaginei ed ossei,e prodotto ottenuto
AU8476698A (en) Human mesenchymal stem cells from peripheral blood
CA2338541A1 (en) Genetically modified cd34-negative adherently growing stem cells and their use in gene therapy
FI92258B (fi) Onkostatiini-A:n käyttö diagnostisessa menetelmässä
ES8606396A1 (es) Procedimiento para la preparacion de activadores de plasmi- nogeno de tejidos
HU9300541D0 (en) Ligand to receptor c-kit qnd method for its utilization
DE3268915D1 (en) Angiotropins of leukocytes and inflamed tissue: a new class of natural chemotropic protein mitogens for specific induction of directional growth of blood vessels, neovascularization of tissues and morphogenesis of blood vessel patterns, process for their biotechnical preparation and pharmaceutical compositions
HUP9901908A2 (hu) p16 Expressziós konstrukciók és alkalmazásuk rákterápiában
BG60238B1 (bg) Човешки тумор- некротизиращ фактор
ES2074049T3 (es) Regulador del crecimiento relacionado con plaquetas.
DK0722336T3 (da) Rekombinant kaffebönne alfa-galactosidase
Weichselbaum et al. Cellular X-ray repair parameters of early passage squamous cell carcinoma lines derived from patients with known responses to radiotherapy
Dayan et al. Ancient neurilemmoma (schwannoma) of the oral cavity
IL122455A0 (en) Hapten modified tumor cell extract and methods of treating or screening for cancer
Inoue et al. Solitary benign schwannoma of the brachial plexus
DE60038680D1 (de) Antisense-therapie für hormonregulierte tumoren
DE3880032D1 (de) Expressionsvektoren fuer die produktion von humanem gm-csf in saengerzellen.
DE3787185D1 (de) Methode zur Erhöhung des Wachstums des Brustzellgewebes.
CA2095335A1 (en) Cell growth inhibitors
EP0516845A4 (en) NEW MEGAKARYOCYTIC COLONY-STIMULATING FACTOR AND METHOD FOR THE PRODUCTION THEREOF.
DK0538330T3 (da) Beta-Alethin-anvendelse til celledyrkning og terapi
Sekiya et al. High-and low-tumorigenic culture lines of rat uterine adenocarcinoma and their isozyme patterns of lactate dehydrogenase and hexokinase
WO1997040073A3 (de) BIOLOGISCH AKTIVER EIWEISSSTOFF - KOLLAGENFRAGMENT HF-COLL-18/514cf - ZUR HEMMUNG DES WACHSTUMS VON TUMOREN UND VON GEFÄSSWUCHERUNGEN